Search

Displaying results 6311 - 6320 of 7067 in total
  1. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

    Mixtures: VAPRINEXT-D, Mlp A-2Synonyms: DL-Bupivacaine, dl-1-Butyl-2',6'-pipecoloxylidide
  2. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity

  3. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.

  4. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    Ethanolamine oleate is a mild sclerosing agent. … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: Oleate de monoethanolamine, Oleato de monoetanolaminio
  5. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).

  6. Drug

    Triptorelin

    go.drugbank.com/drugs/DB06825
    ApprovedInvestigationalVet approved

    Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).

    Synonyms: (D-Trp6)-GnRH, pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Products: Pamorelin LA 22,5 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, Pamorelin LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension
  7. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  9. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

  10. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.